Facebook

Twitter

Linkedin

Pinterest

Email

Clinical Trials Search

Clinical Trial 21209

Cancer Type: Multiple
Study Type: Treatment
NCT#: NCT04242147

Phase: Phase I
Principal Investigator: Tarhini, Ahmad

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase 1, Open Label, Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy of KD033 In Subjects With Metastatic Or Locally Advanced Solid Tumors

Summary

Objective

Primary Objectives: * Dose escalation: To determine the safety/tolerability and the maximum tolerated dose (MTD) of KD033 in subjects with confirmed advanced and/or metastatic solid tumors. * Dose expansion: To confirm the safety/tolerability and the recommended phase 2 dose (RP2D) of KD033 Secondary Objectives: * To characterize the serum pharmacokinetics (PK) and immunogenicity of KD033 * To evaluate the immune correlates of KD033 in peripheral blood * To evaluate efficacy: best overall response (BOR) and duration of response (DOR)

Treatments

Therapies

Immunotherapy

Medications

KD033 (); Not Applicable ()

Inclusion Criteria

Inclusion Criteria:

Histologically or cytologically confirmed/documented advanced and/or metastatic solid tumor with at least one tumor lesion of location accessible to biopsy per clinical judgement of treating physician.

Measurable disease per RECIST v1.1 guidelines.

Life expectancy of at least 3 months.

Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≤ 1.

Adequate organ and bone marrow functions.

All toxicities related to prior radiotherapy, chemotherapy, or surgical procedure must have recovered to baseline or Grade ≤ 1 based on NCI-CTCAE v5.0 except alopecia (any grade), Grade 2 peripheral neuropathy and adverse events that are clinically non significant or stable on supportive care.

All patients, male and female, who are not surgically sterilized or postmenopausal must agree to use "highly effective methods of contraception" during the study and for at least 60 days after the last dose of KD033.

Women of childbearing potential must have a negative pregnancy test within 7 days prior to KD033 treatment.

Ability to understand the purpose of the study, provide signed and dated informed consent from the patient/legal representative prior to performing any protocol-related procedures and able to comply with the study procedures and any locally required authorization.

Patients must be willing to provide a tumor biopsy at the following time points: Pre-treatment and at Cycle 4, Day 1. All other study eligibility criteria must be met before any biopsy sample is obtained.

Other criteria may apply

Exclusion Criteria

Exclusion Criteria:

Use of immunotherapy, biological therapy, cytokine therapy > Use of immunomodulating agents > Use of chemotherapy and approved tyrosine kinase inhibitor (TKI) therapy > Anti PD-L1 or anti PD-1 therapy > Radiotherapy within 14 days before the start of trial treatment (prior diagnostic biopsy is permitted), with the exception of palliative radiation as described: patients assigned to radiotherapy require at least 1 additional lesion that can be safely irradiated while sparing the index lesion(s), and for which radiation at the limited, palliative doses contemplated would be considered medically appropriate; The lesion should be causing some signs or symptoms (e.g., tumor-related pain), for which radiation is indicated per the physician's standard clinical practice.

Use of any investigational drug or have major surgery within 28 days before the start of trial treatment

Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required systemic immunosuppressive treatments.

Systemic therapy with immunosuppressive agents including corticosteroids within 14 days before the start of trial treatment.

Rapidly progressive disease which, in the opinion of Investigator, may predispose to inability to tolerate treatment or trial procedure.

History or clinical evidence of central nervous system primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, demonstrated no progression at least 1 months, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before Screening - Subjects with suspected brain metastases at Screening should undergo a CT/MRI of the brain prior to study entry.

Receipt of any organ transplantation including hematopoietic cell transplantation.

Has a paraneoplastic syndrome of autoimmune nature.

History of interstitial lung disease or severe obstructive pulmonary disease.

Clinically significant cardiovascular/cerebrovascular disease.

QTc(F) interval > 450 ms for men or > 470 ms for women)

Left ventricular ejection fraction (LVEF) > Active infection requiring therapy.

Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding.

Pregnant or breast-feeding women

Known severe hypersensitivity reactions to monoclonal antibodies, any history of or recent (within 6 months) of anaphylaxis

Caccine administration within 4 weeks of investigational drug administration. Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines like inactivated influenza vaccines is allowed. COVID-19 vaccines are approved to be administered prior to KD033 administration and during the treatment phase,; however, it is preferred to not vaccinate during the 28-day DLT period.

Other protocol-defined exclusion criteria could apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.